Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-041032
Filing Date
2024-04-03
Accepted
2024-04-03 16:02:38
Documents
1
Period of Report
2024-04-01

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1623
  Complete submission text file 0000950170-24-041032.txt   3131
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Issuer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O POSEIDA THERAPEUTICS 9390 TOWNE CENTRE DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address
Rizvi Syed Ali-aamir (Reporting) CIK: 0001897621 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39376 | Film No.: 24818622